Review Reports
- Seongjoon Park 1,*,
- Toshimitsu Komatsu 2 and
- Isao Shimokawa 4,5
- et al.
Reviewer 1: Raghu Ramanathan Reviewer 2: Anonymous
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThe manuscript major edits before its acceptance
Major Queries:
1. The mechanistic evidence that ZFP90 suppress NF-KB signaling needs more additional data such as NF-KB luciferase reporter assay, p65 DNA binding assay IkBα. Degradation to strengthen the paper.
2. The manuscript is written based on whole body knockout mice and TRIM28 is shown to bind ZFP90 but there is no loss of function or gain of function experiments showing TRIM28.
3. The MASH studies need more detailed analysis such as sirus Red staining, masson trichrome , NAS score, fibrosis stages and collagen quantification.
4. The (n) number for human subjects need to be increased to get a better analysis.
5. Increased ZFP90 expression in patients contradics knockout phenotype. Explan ?
6. The immune cell analysis is not complete and no immune cell infiltration data is provided.
7. The MT-2 cell used in this study is not ideal model as it’s a HTLV-1 transformed T-cell line so primary murine cells or human peripheral T cells would be required to strengthen the manuscript.
8. Why only male mice was used given well established sex differences in MASLD gender should be used.
Minor Queries:
1. There are few typographical errors.
2. Clarif 20 week HFD model develops MASH or only steatosis.
Comments for author File:
Comments.pdf
Author Response
We would like to thank the reviewer for the thorough and constructive evaluation of our manuscript. We have carefully considered all the comments and performed additional experiments and analyses to address the concerns raised. We believe these revisions have significantly strengthened the mechanistic insights and overall clarity of our findings.
Please see the attachment.
Author Response File:
Author Response.pdf
Reviewer 2 Report
Comments and Suggestions for Authors I have reviewed the manuscript entitled "ZFP90 serves as a transcriptional brake on NF-κB signaling to attenuate diet-induced MASLD progression" by Park S. et al. The authors, despite focusing on a toping of emerging interest, should consider all the issues mentioned below and appropriately revise their manuscript to enable further consideration for publication. Major issues 1) The manuscript reports that male Zfp90 knockout and WT mice on a C57BL/6 background were used, that exon 3 of Zfp90 was deleted, and that 12-week-old male mice were assigned to chow or 60% kcal HFD for 20 weeks. Housing is described only briefly as SPF, 21–24°C, 12 h light/dark cycle, with ad libitum water and CRF-1 diet. However, this is not sufficiently detailed for ARRIVE-compliant assessment. The manuscript should add: i) mouse source/provenance, substrain, backcrossing/littermate strategy, genotype confirmation, and health-monitoring status; ii) number of mice per cage, cage type, bedding, nesting/enrichment, humidity, diet composition/product number, and acclimatization period; iii) whether the experimental unit was the individual mouse or cage, especially for diet/food intake; iv) full procedural details for micro-CT, blood sampling, GTT, LPS injection, euthanasia, tissue collection, and NPC isolation; v) anesthesia, analgesia, monitoring frequency, humane endpoints, and adverse-event reporting. The ARRIVE checklist itself says housing/husbandry, animal care/monitoring, and pain/distress minimization should be reported, but the authors mostly refer back to Section 2.1, where those details are largely absent.2) There are inconsistencies in approval numbers/dates. In Methods 2.1, animal procedures are said to have been approved by the Ethics Review Committee for Animal Experimentation at Nagasaki University under Permit No. 25080703, approval date July 31, 2025. However, the institutional statement later lists animal protocols 1909171569 and 2404301945 with 2024 approval dates, while the human study is also linked to Permit No. 25080703. Please clarity. 3) The manuscript states that mice were “randomly assigned” to diet groups, but does not describe the randomization method, allocation concealment, or how cage/location/order effects were controlled. Blinding is also not adequately reported. The checklist refers to Section 2.7, but that section only describes tissue fixation, H&E staining, imaging, and ImageJ quantification; it does not state who was blinded during conduct, outcome assessment, image analysis, western blot quantification, or statistical analysis. 4) The statistical section says data are mean ± SEM and were analyzed by unpaired two-tailed Student’s t-test or two-way ANOVA with Bonferroni correction. However, repeated measurements, such as body weight, food intake, and GTT time-course data, require repeated-measures ANOVA or mixed-effects models, not multiple t-tests. 5) The study uses global Zfp90 knockout mice. Therefore, the data cannot distinguish adipocyte-, hepatocyte-, immune-cell-, or developmental effects. The authors themselves note the need for conditional knockout models. 6) The mechanistic model is not yet convincing. Co-IP was performed in overexpressing COS-7 cells, not endogenously in liver or relevant immune cells. The functional NF-κB claim rests mainly on LPS-induced Tnfa/Ccl2 expression in NPCs and nuclear p65 western blotting. 7) The manuscript concludes altered intrahepatic T-cell dynamics based on bulk liver mRNA markers and T-cell-line knockdown. Bulk Cd4/Cd8a/Tlr7/Tnfa expression does not establish changes in T-cell number, subset composition, activation state, or Treg function. Tlr7 is not T-cell-specific. 8) Regarding figure 3E, the blot is difficult to interpret. The p-Akt band appears weak and close to other nonspecific bands, and the total Akt panel should be shown with full molecular-weight context. 9) Regarding Figure 5D, the authors interpret this as increased nuclear p65 in KO liver. However, the Methods do not describe nuclear fractionation, and the western blot methods do not list anti-p65 or anti-Lamin B1 antibodies. 10) The manuscript reports fasting glucose, insulin, and reduced p-Akt(Ser473) in eWAT. However, it is unclear whether p-Akt was assessed after acute insulin stimulation or under basal conditions.
Author Response
We would like to thank the reviewer for the thorough and detailed evaluation of our manuscript, particularly regarding the methodological rigor and clarity of our animal experiments. We fully acknowledge the importance of the ARRIVE guidelines and have significantly revised our Methods section to address all requested transparency and technical details. Furthermore, in response to your suggestion, we have upgraded all figures to a high-resolution format of 600 dpi to ensure maximum clarity and professionalism. We have also provided additional explanations and data to clarify the points concerning our experimental results and statistical analyses. We have also provided additional explanations and data to clarify the points concerning our experimental results and statistical analyses.
Please see the attachment.
Author Response File:
Author Response.pdf
Round 2
Reviewer 2 Report
Comments and Suggestions for AuthorsAll comments / issues have been addressed adequately. The manuscript has been substantially improved. There are no additional comments raised.